SEC Form 4 · accession 0000886163-15-000079
LIGAND PHARMACEUTICALS INC · LGND
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles S Berkman
Officer — VP, Gen. Counsel & Secretary
Period of report
Jul 10, 2015
Accepted (ET)
Jul 14, 2015 · 7:35 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000886163
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 10, 2015 | M | 5,625 | $10.05 | A | 32,079 | D | |
| Common StockF1 | Jul 10, 2015 | M | 8,442 | $14.47 | A | 40,521 | D | |
| Common StockF1,F2 | Jul 10, 2015 | S | 2,404 | $98.15 | D | 38,117 | D | |
| Common StockF1,F3 | Jul 10, 2015 | S | 8,838 | $99.18 | D | 29,279 | D | |
| Common StockF1,F4 | Jul 10, 2015 | S | 2,825 | $99.86 | D | 26,454 | D | |
| Common Stock | Jul 13, 2015 | M | 1,000 | $53.10 | A | 27,454 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1,F5 | $10.05 | Jul 10, 2015 | M | 5,625 | D | — | Feb 17, 2021 | Common Stock | 5,625 | 0 | D |
| Employee Stock Option (right to buy)F6 | $53.10 | Jul 13, 2015 | M | 1,000 | D | — | Dec 8, 2015 | Common Stock | 1,000 | 0 | D |
| Incentive Stock Option (right to buy)F1,F7 | $14.47 | Jul 10, 2015 | M | 8,442 | D | — | Feb 9, 2022 | Common Stock | 8,442 | 4,688 | D |
Explanation of responses
- F1The sale(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 09, 2015, in accordance with Rule 10b5-1.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.60 to $98.53, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.66 to $99.585, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.71 to $100.20, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/17/11.
- F6Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 12/8/05.
- F7Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/09/12.